The Sage Group, Inc. has partnered with T-Capital in Shanghai to extend our global reach into the People’s Republic of China. The principal objective is to broaden Sage's strategic licensing, M&A and partnering capabilities for ourhealthcare clients in pharmaceuticals, biopharmaceuticals, biotechnology, diagnostics and medical technology. This will build upon Sage’s 25 years of experience in such transactions.
The Sage Group now offers clients a full strategic advisory service including:
Assisting our clients in the West with licensing their pharma, diagnostic and medtech assets into the dynamic healthcare market in the Republic of China
Assisting Chinese companies with out-licensing their assets into global markets with a focus on North America and Europe
This initiative follows on from increasing demand from our Western and Chinese clients for assistance in conducting cross-border strategic transaction initiatives to assist them in licensing and divesting their assets, and also our clients seeking new assets for in-licensing into North America, Europe and China.
For a confidential discussion in more detail, please emails us China@sagehealthcare.com.
About The Sage Group and T-Capital (together "Sage China")
The Sage Group is a senior-level health care, technology oriented, strategy and transaction advisory firm formed in 1994. The team of highly experienced healthcare executives has substantial strategic, analytical, and hands-on operating experience in the clinical, regulatory and product development disciplines as well as extensive backgrounds in licensing (in and out), corporate partnering, and M&A. The Sage Group Principals have worked on more than 300 transactions with its clients over its existence.
For T-Capital, the Sage China partnership is led by Dr. Yueyue (Linda) Wang, Managing Partner of T-Capital based in Shanghai. Dr. Wang has a Ph.D in Molecular Biology and MBA. She has engaged in dozens of licensing, technology transfer, co-development, JV, investment, M&A, and spin-off programs while working with Eli Lilly, Shyndec (600420.SH), and Sinopharm Investment, where she was managing partner of Industry Development. With internal experienced partners, T-capital has successfully closed dozens of transactions for leading Chinese biotechs, medtechs and large pharmas, with extensive experience in sourcing, deal structuring, deal terms suggesting, deal terms negotiating and closing significant transactions for their clients.
For more information about The Sage Group and opportunities for collaboration with Sage China services, please visit our website, www.sagehealthcare.com, or contact:
US Corporate Office
The Sage Group Inc.
1802 Route 31 North, #381
Clinton, NJ 08809 USA
Attn: Wayne Pambianchi
Phone: +1 908-2319644
EU Corporate Office
Sage Healthcare Ltd.
The Old Black Barns
Lord’s Lane, Ousden, Newmarket CB8 8TX UK
Attn: Dr. Bill Mason
Phone: +44 1638 500775
Mob: +44 7785 950134
Sage China Corporate Office (T-Capital)
Dr. Linda Wang
Managing Partner, Ph.D, MBA
Xuhui Road 3, Shanghai, China
Xuhui Road 3, Shanghai, China